Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetrodotoxin-resistant (TTX-R) voltage-gated sodium channels, primarily comprising the Nav1.8 (SCN10A) and Nav1.9 (SCN11A) isoforms, are critical mediators of excitability in peripheral sensory neurons [PMID: 23333502]. These channels are predominantly expressed in the dorsal root ganglion (DRG) and trigeminal ganglion, where they play a fundamental role in the initiation and propagation of action potentials in nociceptors [PMID: 24021961]. Unlike TTX-sensitive channels, Nav1.8 and Nav1.9 exhibit distinct kinetic properties, such as slow inactivation, which allow them to support repetitive firing during sustained noxious stimuli or inflammatory states [PMID: 10433265]. Their restricted expression in the peripheral nervous system makes them highly attractive therapeutic targets for treating chronic pain conditions, such as neuropathic and inflammatory pain, with a reduced risk of central nervous system or cardiac side effects [PMID: 38570519]. Recent clinical developments, such as the selective Nav1.8 inhibitor suzetrigine (VX-548), have demonstrated the potential for these channels to provide effective analgesia without the addictive properties or respiratory risks associated with opioids [Vertex Pharmaceuticals, 2024].
Blockade of the alpha-subunit pore of Nav1.8 and Nav1.9 channels, which prevents the influx of sodium ions required for membrane depolarization, thereby inhibiting the generation and conduction of pain-related action potentials in peripheral sensory neurons [PMID: 23333502].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetrodotoxin-resistant voltage-gated sodium channels (TTX-R VGSCs).